Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft.
Explore this paper's citation graph
Summary
The co-encapsulated liposome formulation was shown to significantly improve the survival of the tumor-bearing animals, and was possibly due to the increase in systemic drug exposure, with the maintenance of the synergistic molar drug ratio of 1:1 in circulation.
- Type
- article
- Published
- 2013-10-26
- Cited by
- 21
- References
- 0
- OpenAlex
- https://openalex.org/W1976973079
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3698940
Keywords
Liposome, Irinotecan, Drug, Doxorubicin, Pharmacology
References
No references recorded for this paper.
Cited by
- Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine
- Improved oral bioavailability of capsaicin via liposomal nanoformulation: preparation, in vitro drug release and pharmacokinetics in rats
- Extracellular vesicles as drug delivery systems: lessons from the liposome field.
- Synergistic Antitumor Activity of Camptothecin-Doxorubicin Combinations and their Conjugates with Hyaluronic Acid
- Drug–carrier interaction analysis in the cell penetrating peptide-modified liposomes for doxorubicin loading
- Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer
- Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer.
- Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations.
- PRCosomes: pretty reactive complexes formed in liposomes
- Formulation, characterization and anti-tumor synergistic evaluation of Nano emulsion formulation containing Curcumin and Brucea javanica oil
- Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape
- Characterization of pegylated and non‐pegylated liposomal formulation for the delivery of hypoxia activated vinblastine‐N‐oxide for the treatment of solid tumors
- Desenvolvimento de lipossomas vetorizados ao receptor folato contendo paclitaxel e imatinibe coencapsulados: avaliação da atividade antiproliferativa e da expressão gênica do VEGF em células tumorais
- Nano drug delivery systems for ovarian cancer therapy
- Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer
- Nanoparticles for Effective Combination Therapy of Cancer
- Development of ultrasound triggered drug delivery systems for cancer treatment
- Camptothecin Inhibits Neddylation to Activate the Protective Autophagy Through NF-κB/AMPK/mTOR/ULK1 Axis in Human Esophageal Cancer Cells
- Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer
- Versatile Encapsulation and Synthesis of Potent Therapeutic Liposomes by Thermal Equilibration
Related papers
- Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
- UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
- Irinotecan and colorectal cancer: the role of p53, VEGF-C and α-B-crystallin expression
- Comprehensive genetic definition of susceptibility to toxic side effects of irinotecan in mice.
- Irinotecan and UFT/leucovorin in patients with advanced cancers.
- Irinotecan in small cell lung cancer
- Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
- Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
- Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.